v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical)
$ in Thousands
9 Months Ended
Sep. 30, 2026
USD ($)
Cash acquired in connection with the acquisition of Oratech $ (6,500) [1],[2]
Proceeds from Secured Notes Payable 1,025 [3],[4]
Proceeds from issuance of New Notes derivative liabilities and warrant liabilities 4,397
Registered Direct [Member]  
Issuance expenses 558
Market Offering [Member]  
Issuance expenses 162
Public Offering [Member]  
Issuance expenses $ 391
[1] Represents cash acquired in connection with the acquisition of Oratech from Oramed Pharmaceuticals Inc., a related party, of $6,500.
[2] See Note 6.
[3] Represents proceeds from issuance of Additional Notes to Oramed Pharmaceuticals Inc., a related party, of $1,025 for the six months ended June 30, 2026.
[4] See Note 9a.